Serina Therapeutics (NYSE: SER) holders back major share and equity plan increases
Filing Impact
Filing Sentiment
Form Type
8-K
Rhea-AI Filing Summary
Serina Therapeutics, Inc. reported that stockholders approved a major amendment to its charter, increasing authorized common stock from 40,000,000 to 125,000,000 shares effective June 17, 2026. This gives the company significantly more capacity to issue new shares in the future.
At the 2026 Annual Meeting, stockholders elected three directors to terms ending at the 2029 meeting. They also approved adding 2,000,000 shares to the 2024 Equity Incentive Plan, authorized issuances of common stock tied to conversion of Series A Preferred Stock and certain private placement securities, supported executive compensation and annual say‑on‑pay votes, and ratified Frazier & Deeter, LLC as auditor for 2026.
Positive
- None.
Negative
- None.
Insights
Serina’s shareholders approved a large increase in authorized shares plus multiple equity-related proposals.
The increase in authorized common stock from 40,000,000 to 125,000,000 shares materially expands the company’s ability to issue equity for financing, compensation, conversions, or acquisitions. Shareholder approval ties the change to a clear governance process at the 2026 Annual Meeting.
Investors also backed a 2,000,000-share expansion of the 2024 Equity Incentive Plan and approved issuances for converting Series A Preferred Stock and certain private placement securities into common stock. Advisory say‑on‑pay and an annual frequency for such votes passed, and Frazier & Deeter, LLC was ratified as the independent registered public accounting firm for the 2026 fiscal year.
8-K Event Classification
3 items: 5.03, 5.07, 9.01
3 items
Item 5.03
Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Governance
The company amended its charter documents, bylaws, or changed its fiscal year.
Item 5.07
Submission of Matters to a Vote of Security Holders
Governance
Results of a shareholder vote on proposals at an annual or special meeting.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Key Figures
Authorized common stock (new): 125,000,000 shares
Authorized common stock (prior): 40,000,000 shares
Equity plan share increase: 2,000,000 shares
+3 more
6 metrics
Authorized common stock (new)
125,000,000 shares
Authorized common stock after June 17, 2026 amendment
Authorized common stock (prior)
40,000,000 shares
Authorized common stock before amendment
Equity plan share increase
2,000,000 shares
Additional shares for 2024 Equity Incentive Plan
Share increase proposal support
9,066,239 For / 478,876 Against
Vote on increasing authorized common stock to 125,000,000
Auditor ratification vote
9,964,933 For / 265,157 Against
Ratification of Frazier & Deeter, LLC for 2026
Director vote example
4,732,486 For / 15,785 Withheld
Election of Gregory H. Bailey, M.D.
Key Terms
Certificate of Amendment, 2024 Equity Incentive Plan, Series A Preferred Stock, Private Placement Securities, +2 more
6 terms
Certificate of Amendment regulatory
"filed a certificate of amendment (the “Certificate of Amendment”) to the Company’s First Amended and Restated Certificate of Incorporation"
A certificate of amendment is an official filing that updates a company’s founding documents—its legal “rulebook” that sets share structure, voting rules, name and basic purpose. Think of it like changing the blueprint of a building: small changes are paperwork, big ones can alter who owns how much and who controls decisions. Investors watch these filings because they can affect share counts, voting power, dilution and company value.
2024 Equity Incentive Plan financial
"a proposed amendment to the Serina Therapeutics, Inc. 2024 Equity Incentive Plan to increase the number of shares"
Series A Preferred Stock financial
"the issuance of common stock in connection with the conversion of certain existing Series A Preferred Stock into common stock"
Series A preferred stock is a type of ownership share in a company that gives investors certain advantages, such as priority in receiving profits or getting their money back if the company is sold or goes bankrupt. It is often issued during early funding stages to attract investors by offering more security than common shares. This stock matters to investors because it provides a safer way to invest while still holding potential for future gains.
Private Placement Securities financial
"the issuance of common stock in connection with the exercise of certain existing Private Placement Securities into common stock"
Securities sold directly to a small group of chosen investors—often well‑capitalized individuals or institutions—rather than offered to the general public on an exchange. Think of it as a private sale instead of a public auction: it lets a company raise money more quickly and with fewer disclosure rules, but can dilute existing owners, reduce liquidity for those securities, and signal how investors view the company’s prospects, all of which matter to shareholders.
Say-on-Pay financial
"the compensation of the Company’s Named Executive Officers was approved on an advisory basis by the following vote"
A say-on-pay is a shareholder vote that gives investors a chance to approve or disapprove a company’s executive compensation packages, typically held at annual meetings. It matters because the vote signals investor satisfaction with how leaders are paid—like customers rating how well managers are rewarded—and can push boards to change pay plans, reducing governance risk and affecting investor confidence and stock value even though the vote is usually advisory rather than legally binding.
independent registered public accounting firm financial
"Ratification of the appointment of Frazier & Deeter, LLC as the Company’s independent registered public accounting firm for the 2026 fiscal year"
An independent registered public accounting firm is an outside accounting company officially registered with the government regulator to examine and report on a public company's financial records and controls. Investors treat its reports like an impartial inspector’s certificate — they add credibility to financial statements, help spot errors or misleading claims, and reduce the risk that shareholders are relying on unchecked or biased numbers.
FAQ
What happened at Serina Therapeutics’ 2026 Annual Meeting of Stockholders?
At the 2026 Annual Meeting, Serina Therapeutics’ stockholders elected three directors, approved a major increase in authorized common stock, expanded the 2024 Equity Incentive Plan, authorized certain stock issuances, endorsed executive pay on an advisory basis, and ratified Frazier & Deeter, LLC as auditor for 2026.
Were Serina’s proposals on preferred stock conversion and private placement securities approved?
Yes. Stockholders approved the issuance of common stock upon conversion of certain existing Series A Preferred Stock and upon exercise of certain existing Private Placement Securities. These approvals allow those instruments to be settled in common shares under the terms described in the proxy materials.
How did Serina Therapeutics’ say-on-pay and say-on-pay frequency votes turn out?
Stockholders approved the compensation of Named Executive Officers on an advisory basis and supported holding future say‑on‑pay votes every one year. This indicates shareholder acceptance of the current pay program and a preference for annual advisory input on executive compensation.
Who is Serina Therapeutics’ independent auditor for the 2026 fiscal year?
Stockholders ratified Frazier & Deeter, LLC as Serina Therapeutics’ independent registered public accounting firm for the 2026 fiscal year. Ratification confirms shareholder support for the existing audit relationship overseeing the company’s financial statement auditing and related services.